Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 10.15 USD 5.84% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Applied Therapeutics Inc?
Write Note

Net Margin
Applied Therapeutics Inc

-2 578.2%
Current
-853%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 578.2%
=
Net Income
-269.4m
/
Revenue
10.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Applied Therapeutics Inc
NASDAQ:APLT
1.2B USD
-2 578%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-14%
Country US
Market Cap 1.2B USD
Net Margin
-2 578%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.7B USD
Net Margin
9%
Country US
Market Cap 147.4B USD
Net Margin
13%
Country US
Market Cap 119.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.3B EUR
Net Margin
-14%
No Stocks Found

Applied Therapeutics Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
6.73 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 578.2%
=
Net Income
-269.4m
/
Revenue
10.4m
What is the Net Margin of Applied Therapeutics Inc?

Based on Applied Therapeutics Inc's most recent financial statements, the company has Net Margin of -2 578.2%.